Literature DB >> 26034813

QSAR study of some anti-hyperglycaemic sulphonylurea drugs.

J C Dearden1, M Hewitt, P H Rowe.   

Abstract

Sulphonylureas are widely used anti-hyperglycaemic drugs for the treatment of type 2 diabetes. The only published quantitative structure-activity relationship (QSAR) models for sulphonylurea drugs have been found to be questionable, for a number of reasons. We have re-analysed the human anti-hyperglycaemic potencies, acute mouse intraperitoneal toxicities (LD50) and plasma protein-binding abilities of the 15 drugs using multiple linear regression and obtained good QSAR models for each endpoint. The obtained QSARs all comply well with the Organisation for Economic Co-operation and Development (OECD) Guidelines for the Validation of (Q)SARs. We could not carry out external validation of our models for acute toxicity and plasma protein-binding because of the very small datasets available.

Entities:  

Keywords:  QSAR; anti-hyperglycaemic activity; plasma protein-binding; potency; sulphonylureas; toxicity

Mesh:

Substances:

Year:  2015        PMID: 26034813     DOI: 10.1080/1062936X.2015.1046189

Source DB:  PubMed          Journal:  SAR QSAR Environ Res        ISSN: 1026-776X            Impact factor:   3.000


  1 in total

1.  Within-Sulfonylurea-Class Evaluation of Time to Intensification with Insulin (ZODIAC-43).

Authors:  Dennis Schrijnders; Laura C Hartog; Nanne Kleefstra; Klaas H Groenier; Gijs W D Landman; Henk J G Bilo
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.